Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Type III hypersensitivity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Type III hypersensitivity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-003248-36 Sponsor Protocol Number: 61383082 Start Date*: 2011-09-30
    Sponsor Name:Central Military Hospital
    Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.
    Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016335 Feeling hot and cold LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037872 Rash NOS LLT
    14.0 10037175 - Psychiatric disorders 10032168 Other insomnia LLT
    14.0 10007541 - Cardiac disorders 10008481 Chest pain - cardiac LLT
    14.0 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    14.0 10029205 - Nervous system disorders 10048324 Dizziness aggravated LLT
    14.0 10029205 - Nervous system disorders 10033777 Paraesthesia distal LLT
    14.0 10022891 - Investigations 10050786 Fasting blood glucose increased LLT
    14.0 10018065 - General disorders and administration site conditions 10022096 Injection site reaction NOS LLT
    14.0 10021881 - Infections and infestations 10034838 Pharyngitis NOS LLT
    14.0 10018065 - General disorders and administration site conditions 10016259 Fatigueability LLT
    14.0 10021428 - Immune system disorders 10020762 Hypersensitivity type I LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048412 Back pain aggravated LLT
    14.0 10021428 - Immune system disorders 10020756 Hypersensitivity reaction LLT
    14.0 10017947 - Gastrointestinal disorders 10028822 Nauseated LLT
    14.0 10047065 - Vascular disorders 10048347 Flushing aggravated LLT
    14.0 10029205 - Nervous system disorders 10024857 Loss of consiousness LLT
    14.0 10029205 - Nervous system disorders 10019218 Headache NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037096 Pruritus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003699-60 Sponsor Protocol Number: KIBB01 Start Date*: 2018-09-28
    Sponsor Name:Karolinska Institutet
    Full Title: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal...
    Medical condition: Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV.
    Disease:
    Population Age: In utero, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004892-36 Sponsor Protocol Number: SLE subcuvia 04 Sep 2006 Start Date*: 2007-03-15
    Sponsor Name:Department of Rheumatology,University hospital,Lund
    Full Title: An open randomized and comparative study on the efficacy and safety of additional treatment of subcutaneous immunoglobulin (Subcuvia) during cessation of Prednisolon in patients with active systemi...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040967 SLE LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006302-13 Sponsor Protocol Number: CT-BI Vacc-4x 2007/1 Start Date*: 2008-06-04
    Sponsor Name:Bionor Immuno AS
    Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART
    Medical condition: HIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 ...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000727-42 Sponsor Protocol Number: CYT004-MelQbG10 01 Start Date*: 2006-01-20
    Sponsor Name:Cytos Biotechnology AG
    Full Title: A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A-VLP Vaccine in HLA-A2 Positive Patients with stage III/IV Malignant Melanoma
    Medical condition: Patients with Stage III/IV Malignant Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004457-40 Sponsor Protocol Number: SL0023 Start Date*: 2016-09-19
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY FOLLOWED BY AN OBSERVATIONAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN SU...
    Medical condition: SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10040967 SLE LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed) HU (Completed) BG (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004105-28 Sponsor Protocol Number: 291-420 Start Date*: 2006-06-20
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.
    Medical condition: Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC).
    Disease: Version SOC Term Classification Code Term Level
    8.0 10045265 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) NL (Ongoing) GR (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017422-39 Sponsor Protocol Number: 26091 Start Date*: 2010-12-23
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.
    Medical condition: Recurrent grade II and grade III gliomas
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027744 Mixed astrocytoma-oligodendroglioma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060971 Astrocytoma malignant PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026659 Malignant oligodendroglioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004433-18 Sponsor Protocol Number: PENTA 15 Start Date*: 2006-02-13
    Sponsor Name:PENTA
    Full Title: PLASMA PHARMACOKINETIC STUDY OF ONCE VERSUS TWICE DAILY ABACAVIR AS PART OF COMBINATION ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV-1 INFECTION AGED 3 MONTHS TO < 36 MONTHS
    Medical condition: Paediatric HIV infection
    Disease: Version SOC Term Classification Code Term Level
    8 10020161 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003482-17 Sponsor Protocol Number: 291-418 Start Date*: 2006-03-03
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
    Medical condition: Intravenous steroid-refractory ulcerative colitis (IVSR-UC)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10045265 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Prematurely Ended) ES (Ongoing) GR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004691-22 Sponsor Protocol Number: RCT-004 Start Date*: 2017-11-21
    Sponsor Name:Rechon Life Science AB
    Full Title: A Randomised, Open, Parallel-group Phase III Biosimilarity Study to Assess the Long-term Safety, Focusing on Immunogenicity, of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000847-25 Sponsor Protocol Number: EMR63325-013 Start Date*: 2011-07-04
    Sponsor Name:Merck KGaA
    Full Title: A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant ch...
    Medical condition: Rectal cancer subjects undergoing neoadjuvant chemoradiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10038043 Rectal cancer Duke's C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000776-29 Sponsor Protocol Number: P-Monofer-PREG-01 Start Date*: 2017-05-03
    Sponsor Name:Pharmacosmos A/S
    Full Title: Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: a randomised, comparative, open-label trial
    Medical condition: iron deficiency in pregnant women
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10005329 - Blood and lymphatic system disorders 10002041 Anaemia complicating pregnancy, childbirth, or the puerperium LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001659-42 Sponsor Protocol Number: ANTITROMBINA Start Date*: 2020-04-18
    Sponsor Name:Fundación para la Investigación Biomédica de Córdoba
    Full Title: Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19
    Medical condition: Confirmed SARS-CoV-2 respiratory infection with poor prognostic factors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10051905 Coronavirus infection LLT
    20.1 10021881 - Infections and infestations 10061982 Severe acute respiratory syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000424-10 Sponsor Protocol Number: UC-0130/1703 Start Date*: 2017-06-16
    Sponsor Name:UNICANCER
    Full Title: A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).
    Medical condition: Patients with recurrent and/or metastatic platinum refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN), with poor prognosis and no effective chemotherapy options.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002328-34 Sponsor Protocol Number: KB056 Start Date*: Information not available in EudraCT
    Sponsor Name:KEDRION S.P.A
    Full Title: Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, cont...
    Medical condition: Paediatric patients undergoing abdominal or orthopedic surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10067439 Haemostasis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001760-19 Sponsor Protocol Number: THR-1442-C-476 Start Date*: 2016-01-07
    Sponsor Name:Theracos Sub, LLC
    Full Title: A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
    Medical condition: Type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017358-10 Sponsor Protocol Number: D1680C00003 Start Date*: 2010-03-26
    Sponsor Name:AstraZeneca AB
    Full Title: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagl...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) FR (Completed) PL (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000192-37 Sponsor Protocol Number: 2019_0007 Start Date*: 2021-10-04
    Sponsor Name:Hôpital Foch
    Full Title: Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide
    Medical condition: Patients with a diagnosis of Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000547-24 Sponsor Protocol Number: CCRG11-001 Start Date*: 2012-02-27
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study
    Medical condition: Therapeutic vaccination with dendritic cells loaded with Wilms' tumor 1 protein in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.0 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:38:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA